Author: Nichols Martin|| Date Published: July 31, 2020
Pharmaceutical company GlaxoSmithKline has been awarded a $342M contract by the U.S. Army to obtain COVID-19 vaccines in mass quantities from multiple vendors.
The service branch obligated the full contract amount at the time of award to support coronavirus response efforts at military sites within and outside the continental U.S., the Department of Defense said Thursday.
Army Contracting Command received one bid for the procurement.
Contract work will take place at Research Triangle Park in North Carolina through Feb. 28, 2021.
Naval Information Warfare Center Atlantic has issued a solicitation seeking contractor support for shipboard command, control, communications, computers, cyber and intelligence,…
Radiance Technologies has elevated Darien Hammett to chief operating officer, placing him in charge of daily operations and execution across the company.…
latter’sRocket Lab announced Tuesday it has completed the acquisition of Mynaric, a laser-optical communications terminal provider, in a $155.3 million…
GreyNoise Intelligence has launched a command-and-control detection capability designed to give federal agencies earlier visibility into compromised infrastructure. GreyNoise’s new…
